You are here: Home » PTI Stories » National » News
Business Standard

Jubilant Life gets USFDA nod for Niacin extended release tablets

Press Trust of India  |  New Delhi 

today said it has received the final approval from USFDA for its generic extended-release tablets used for controlling levels.

The approval granted by the (USFDA) to the company's wholly-owned arm Jubilant Pharma Ltd, is for multiple strengths of extended-release tablets of 500 mg, 750 mg, and 1,000 mg, the company said in a statement.

These are the generic equivalent of AbbVie's Niaspan, which is indicated to reduce elevated high-density lipoprotein (known as bad cholesterol), among others while increasing HDL-C (good cholesterol) in patients with and

The drug helps reduce the risk of (heart attack) in patients with a and hyperlipidemia, the statement added.

"This is the first approval that we have received from the USFDA during the current financial year," it said.

As on March 31, 2018, Jubilant had a total of 94 ANDAs for oral solids filed in the US, the company said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 15 2018. 16:05 IST